Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Masimo Corp (NQ: MASI )

175.08 +0.70 (+0.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Masimo Corp

< Previous 1 2 3 4 5 6 7 Next >
Citigroup Slashes Price Target On This Stock By 83%; Also Check Out Some Other Big PT Changes
RBC Capital cut the price target for Nuvei Corporation (NASDAQ: NVEI) from $80 to $60. Nuvei shares fell 21.5% to close at $33.03 on Tuesday. 
Via Benzinga
Masimo Clocks 85% Jump In Quarterly Sales, Provides Q3 Guidance Below Expectations
Via Benzinga
7 Best High-Growth Stocks for Young Investors
The best high-growth stocks for young investors are poised to outperform once again once the markets turn positive. 
Via InvestorPlace
Masimo's Return on Invested Capital Insights
According to Benzinga Pro, during Q1, Masimo (NASDAQ:MASI) earned $46.59 million, a 31.74% increase from the preceding quarter. Masimo's sales decreased to $304.24 million, a 7.12% change since Q4. 
Via Benzinga
7 Analysts Have This to Say About Masimo
Masimo (NASDAQ:MASI) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Masimo Posts Better Than Expected Q1 Earnings Despite 'Unexpected' Supply Chain Issues
Via Benzinga
Supply Chain Challenges To Hit Masimo's Q1 FY22 Sales
Via Benzinga
Why Jim Cramer Recommends Buying Norwegian Cruise Line
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norwegian Cruise Line Holdings Ltd. (NYSE... 
Via Benzinga
Is Masimo 'Crazy Like A Fox' For Spending $1.03 Billion To Buy Sound United?
Investors were left scratching their heads after Masimo announced the buyout. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Masimo's Earnings Outlook
Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Masimo will report an... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Goldman Sachs raised the price target on Consolidated Edison, Inc. (NYSE: ED) from $65 to $83. Consolidated Edison shares rose 0.5% to trade at $95.24 on Thursday. 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Analyst Ratings For Masimo
Analysts have provided the following ratings for Masimo (NASDAQ:MASI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings... 
Via Benzinga
Masimo's SedLine Brain Function Monitor Sensor Scores FDA Approval For Pediatric Use
The FDA has FDA cleared Masimo Corp's (NASDAQ: MASI) SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022
Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. The current volume of 639.5K shares is 152.7% of... 
Via Benzinga
Masimo Whale Trades Spotted
Someone with a lot of money to spend has taken a bullish stance on Masimo (NASDAQ:MASI). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
56 Biggest Movers From Yesterday
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead... 
Via Benzinga
Mid-Afternoon Market Update: US Stocks Pare Losses; S&P 500 Turns Higher
US stocks pared losses toward the end of trading on Wednesday following the release of Fed minutes. 
Via Benzinga
MASI Stock: The Masimo-Sound United Deal That Has Investors Scratching Their Heads
Masimo (MASI) stock is falling hard on Wednesday after the company revealed plans to acquire Sound United for a whopping $1.025 billion. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; EIA Reports Unexpected Rise In Crude Inventories
US stocks traded lower midway through trading on Wednesday ahead of the release of Fed minutes. 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower Ahead Of Fed Minutes
US stocks opened on a downbeat note this morning following the release of several economic reports. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 16, 2022
Upgrades According to Compass Point, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Buy. Comerica earned $1.66 in the fourth quarter, compared to $1.49... 
Via Benzinga
Looking Into Masimo's Return On Capital Employed
According to Benzinga Pro, during Q4, Masimo (NASDAQ:MASI) earned $68.26 million, a 18.15% increase from the preceding quarter. Masimo also posted a total of $327.58 million in sales, a 6.56% increase... 
Via Benzinga
Masimo Stock Plunges After Q4 Results, Sound United Deal
Masimo Corp's (NASDAQ: MASI) Q4 product revenue increased 11% Y/Y to $327.6 million, or 11.5% on a constant currency basis, beating the consensus of $320.93 million... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.